瑞士 - 意大利文 - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ponesimodum - compresse rivestite con film - ponesimodum 20 mg, lactosum monohydricum 109.6 mg, cellulosum microcristallinum, povidonum k 30, natrii laurilsulfas, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, hypromellosum, triacetinum, macrogolum 3350, e 171, e 172 (flavum) pro compresso obducto corresp. natrium 1.8 mg. - multiple sklerose - synthetika

瑞士 - 意大利文 - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - imlifidasum - polvere per soluzione per infusione - imlifidasum 11 mg, mannitolum, polysorbatum 80, trometamolum, dinatrii edetas, acidum hydrochloridum, pro vitro corresp. natrium 0.004 mg. - prévention du rejet de greffe suite à la transplantation d’organes solides - biotechnologika

瑞士 - 意大利文 - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - siponimodum - compresse rivestite con film - siponimodum 1 mg ut siponimodi fumaras, excipiens pro compresso obducto. - sekundär progrediente multiple sklerose (spms) bei erwachsenen - synthetika

瑞士 - 意大利文 - Swissmedic (Swiss Agency for Therapeutic Products)

horizon therapeutics switzerland gmbh - inebilizumabum - concentrato per soluzione per infusione - inebilizumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, natrii chloridum, trehalosum dihydricum, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 10 ml corresp., natrium 16.1 mg. - behandlung von erwachsenen patienten mit neuromyelitis-optica-spektrum-erkrankungen (nmosd), die anti-aquaporin-4-immunglobulin g(aqp4-igg)-seropositiv sind - biotechnologika

欧盟 - 意大利文 - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - sclerosi multipla - immunosoppressori - trattamento di pazienti adulti con forme recidivanti di sclerosi multipla (rms) con malattia attiva definita da caratteristiche cliniche o di imaging. trattamento di pazienti adulti con inizio sclerosi multipla progressiva primaria (ppm) in termini di durata di malattia e il livello di disabilità, e con funzioni di imaging caratteristica di attività infiammatoria.

欧盟 - 意大利文 - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - sclerosi multipla recidivante-remittente - immunosoppressori - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

欧盟 - 意大利文 - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus eritematoso, sistemico - immunosoppressori - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

欧盟 - 意大利文 - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosoppressori - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

瑞士 - 意大利文 - Swissmedic (Swiss Agency for Therapeutic Products)

vifor fresenius medical care renal pharma ltd. - avacopanum - capsule rigide - avacopanum 10 mg, macrogolglyceroli hydroxystearas 245 mg, macrogolum 4000, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, gelatina, polysorbatum 80, drucktinte: e 172 (nigrum), pro capsula. - behandlung erwachsener patienten mit schwerer aktiver vaskulitis (granulomatose mit polyangiitis (gpa) oder mikroskopischer polyangiitis (mpa)) - synthetika

欧盟 - 意大利文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psoriasi - immunosoppressori - treatment of moderate-to-severe plaque psoriasis in adults.